Name:
Health Research Board - Emerging Investigator Awards (EIA) 2019 Panel member (Event)
Role:
Member
Year:
2018 - 2019
Name:
EASD NAFLD Study Group (External organisation)
Role:
Member
Year:
2016 - 2019
Name:
NAFLD update
Role:
Speaker
Year:
2018
Name:
Non alcoholic fatty liver disease (NAFLD), what is it, why do we need to worry and what should we do
Role:
Speaker
Year:
2018
Name:
Alcoholic Liver Disease And Risk Of Cardiovascular Disease
Role:
Speaker
Year:
2018
Name:
Non Alcoholic Fatty Liver Disease and Extra-Hepatic Complications
Role:
Speaker
Year:
2018
Name:
Liver and extra-hepatic complications of NAFLD.
Role:
Speaker
Year:
2018
Name:
NAFLD: What is it, why does it matter and what do we need to know?
Role:
Speaker
Year:
2018
Name:
Diagnosis and Management of NAFLD in Patients with and without Diabetes Management
Role:
Speaker
Year:
2018
Name:
NAFLD and Managing Cardiovascular Risk: A Case History
Role:
Speaker
Year:
2018
Name:
AFLD: What is it, why does it matter and what do we need to know
Role:
Speaker
Year:
2018
Name:
What to do about non-alcoholic fatty liver disease?
Role:
Speaker
Year:
2018
Name:
Keynote lecture at Belgian-Dutch Round Table Meeting NAFLD/NASH. Title: UK experiences with cascade of care in NAFLD/NASH.
Role:
Speaker
Year:
2019
Name:
Effects of docosahexanoic acid tissue enrichment on hepatic fat, hepatic insulin sensitivity and markers of disease severity in people with NAFLD
Role:
Speaker
Year:
2014
Name:
Foie gras, diabetes and cardiovascular disease: what’s the link?
Role:
Speaker
Year:
2014
Name:
NAFLD: an important link between chronic liver disease, type 2 diabetes and cardiovascular disease’
Role:
Speaker
Year:
2015
Name:
Lecture at European Association for the Study of the Liver (EASL) International Liver Congress. Title: Management of diabetes in patients with cirrhosis: which treatments, which targets?
Role:
Speaker
Year:
2019
Name:
Lecture at University of Nottingham Medical School, Queen's Medical Centre, Nottingham, UK. Title: NAFLD service from a diabetes expert point of view.
Role:
Speaker
Year:
2019
Name:
Teaching /educational lecture: NIHR CRN clinical fellow trainees about disseminating results to participants in clinical research studies
Role:
Speaker
Year:
2019
Name:
Lecture at British and Irish Hypertension Society (BIHS) Annual Scientific meeting. Title: NAFLD: what is it, what do we need to know and should we worry about cardiovascular risk?
Role:
Speaker
Year:
2019
Name:
Lecture at European Association for the Study of Diabetes (EASD) 55th Annual meeting: EASD NAFLD study group planning meeting. Title: Management of diabetes in patients with cirrhosis: which treatments and which targets?
Role:
Speaker
Year:
2019
Name:
Lecture at 13th European Nutrition Conference of the Federation of European Nutrition Societies (FENS) conference. Title: Non-Alcoholic Fatty Liver Disease and its association with cardiovascular / cardiometabolic disease.
Role:
Speaker
Year:
2019
Name:
Lecture at Oxford Centre for Diabetes, Endocrinology & Metabolism (OCDEM): Title: NAFLD a metabolic liver disease with implications far beyond the liver
Role:
Speaker
Year:
2019
Name:
Lecture at Annual UK Dermatology Course for Consultants 2019
Role:
Speaker
Year:
2019
Name:
Lecture at Belgian Association for the Study of the Liver (BASL) Winter meeting. Title: Screen for NASH in a diabetic population?
Role:
Speaker
Year:
2019
Name:
Lecture at Metabolic Syndrome, Diabetes and NAFLD congress and 3rd Global Nash Congress. Title: Diabetes and NAFLD: a vicious spiral affecting both diseases
Role:
Speaker
Year:
2020
Name:
President Royal Society of Medicine Lipids, Vascular risk section 2013-2016
Role:
Other
Year:
2013
Name:
Lecture at EASD NAFLD study group virtual symposium at (EASD) virtual conference (Vienna): The intestinal microbiome and NAFLD: is modification of the gut microbiota a therapeutic option?
Role:
Speaker
Year:
2020
Name:
Lecture at Virtual Clinical Dermatology Update Meeting, Wrexham Maelor Hospital: NAFLD: relevance to dermatologists with practical management guidance.
Role:
Speaker
Year:
2020
Name:
European Atherosclerosis Society Webinar: Fatty Liver and Cardiovascular Disease: Partners in Crime?. Lecture title: Non-Alcohol Fatty Liver Disease: basics and risk for cardiovascular disease
Role:
Speaker
Year:
2021
Name:
BRC Science Forum lecture. NIHR BRC,UHS/UoS, SGH.
Role:
Speaker
Year:
2021
Name:
NAFLD: a multisystem disease
Role:
Speaker
Year:
2021
Name:
Cardiovascular disease in NAFLD
Role:
Speaker
Year:
2021
Name:
NAFLD/NASH in metabolic syndrome and early type 2 diabetes
Role:
Speaker
Year:
2021
Name:
In NAFLD/NASH
Role:
Speaker
Year:
2021
Name:
Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime.
Role:
Speaker
Year:
2022
Name:
New NICE diabetes guidelines: implications for NAFLD clinics.
Role:
Speaker
Year:
2022
Name:
Diabetes and NAFLD: a vicious spiral of worsening diseases.
Role:
Speaker
Year:
2022
Name:
Diabetes & NASH partners in crime.
Role:
Speaker
Year:
2022
Name:
The complex relationship between type 2 diabetes and non-alcoholic fatty liver disease: what Endocrinologists need to know.
Role:
Speaker
Year:
2022
Name:
The relationship between type 2 diabetes and NAFLD and relevant treatments for NAFLD.
Role:
Speaker
Year:
2023
Name:
Metabolic-associated fatty liver disease: Vascular implications.
Role:
Speaker
Year:
2023
Name:
Type 2 Diabetes & NAFLD: Screening and emerging therapies
Role:
Speaker
Year:
2023
Name:
Managing diabetes in NASH and cirrhosis: treatment and monitoring
Role:
Speaker
Year:
2023
Name:
Implementation of the change for steatotic liver disease: challenges and opportunities
Role:
Speaker
Year:
2024
Name:
Cardiovascular complications
Role:
Speaker
Year:
2024
Name:
Metabolic dysfunction-associated steatotic liver disease (MASLD), triglyceride and cardiovascular risk
Role:
Speaker
Year:
2025
Name:
MASLD: how to recognise it, diagnostic tools, what you need to know, when/where to refer and new therapies
Role:
Speaker
Year:
2025
Name:
Diagnosing and managing metabolic dysfunction-associated steatotic liver disease
Role:
Speaker
Year:
2025
Name:
Heart UK. 39th Annual Medical & Scientific Conference 2026. Advancing CVD Prevention
Role:
Speaker
Year:
2026
Name:
How do we reduce CV risk in patients with MASLD?
Role:
Speaker
Year:
2026
